Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2012年 / 2卷 / 01期
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [41] Adherence to Cholinesterase Inhibitors in Alzheimer's Disease: A Review
    Brady, Roseanna
    Weinman, John
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2013, 35 (5-6) : 351 - 363
  • [42] Rationale for combination therapy with galantamine and Memantine in Alzheimer's disease
    Grossberg, George T.
    Edwards, Keith R.
    Zhao, Qinying
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (07) : 17S - 26S
  • [43] Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis
    Ahuja, Manan
    Siddhpuria, Shailee
    Karimi, Arian
    Lewis, Kaitlin
    Wong, Eric
    Lee, Justin
    Reppas-Rindlisbacher, Christina
    Sood, Emma
    Gabor, Christopher
    Patterson, Christopher
    AGE AND AGEING, 2023, 52 (11)
  • [44] Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
    Zemek, Filip
    Drtinova, Lucie
    Nepovimova, Eugenie
    Sepsova, Vendula
    Korabecny, Jan
    Klimes, Jiri
    Kuca, Kamil
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) : 759 - 774
  • [45] A Meta-Analysis of the Efficacy of Donepezil, Rivastigmine, Galantamine, and Memantine in Relation to Severity of Alzheimer's Disease
    Di Santo, Simona Gabriella
    Prinelli, Federica
    Adorni, Fulvio
    Caltagirone, Carlo
    Musicco, Massimo
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 35 (02) : 349 - 361
  • [46] The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis
    Kishi, Taro
    Matsunaga, Shinji
    Iwata, Nakao
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 1909 - 1928
  • [47] Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia
    Nerattini, Matilde
    Jett, Steven
    Andy, Caroline
    Carlton, Caroline
    Zarate, Camila
    Boneu, Camila
    Battista, Michael
    Pahlajani, Silky
    Loeb-Zeitlin, Susan
    Havryulik, Yelena
    Williams, Schantel
    Christos, Paul
    Fink, Matthew
    Brinton, Roberta Diaz
    Mosconi, Lisa
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [48] Familial Coaggregation of Alzheimer's Disease and Parkinson's Disease: Systematic Review and Meta-Analysis
    Feldman, Adina L.
    Johansson, Anna L. V.
    Lambert, Paul C.
    Sieurin, Johanna
    Yang, Fei
    Pedersen, Nancy L.
    Wirdefeldt, Karin
    NEUROEPIDEMIOLOGY, 2014, 42 (02) : 69 - 80
  • [49] Systematic analysis and prediction of the burden of Alzheimer's disease and other dementias caused by hyperglycemia
    He, Dongying
    Liu, Manting
    Tang, Yujin
    Tian, Xiaona
    Zhou, Lisi
    Chen, Yizhen
    Liu, Xiaoxia
    FRONTIERS IN PUBLIC HEALTH, 2025, 12
  • [50] Meta-analysis of six-month memantine trials in Alzheimer's disease
    Doody, Rachelle Smith
    Tariot, Pierre N.
    Pfeiffer, Eric
    Olin, Jason T.
    Graham, Stephen M.
    ALZHEIMERS & DEMENTIA, 2007, 3 (01) : 7 - 17